From October 12th to 13th, the 3rd China Biologics CMC Conference is held in Hangzhou, hosted by the China Center for Food and Drug International Exchange(CCFDIE), supported by the Center for Drug Evaluation(CDE) of the National Medical Products Administration(NMPA) and the Zhejiang Medical Products Administration, and undertaken by the Hangzhou Administration for Market Regulation. The remarks at the opening ceremony are delivered by Wang Tao, Deputy Director General of the CDE of NMPA, Wang Zhuangwu, Director General of Zhejiang Medical Products Administration, and Pan Wei, Deputy Secretary General of the Hangzhou Municipal People's Government. Wang Xiangyu, Deputy Director General of the CCFDIE, presided over the meeting.

　　The conference closely tracks the cutting-edge primary research and development of drug innovation, promotes communication and interaction between regulatory authorities and the pharmaceutical industry, and strengthens exchange and cooperation in drug regulatory science at home and aboard, so as to deeply implemented a series of instructions on drug safety and technological innovation by Secretary General Xi, especially the guiding principles of the important speech of Secretary General Xi during the inspection tour in Zhejiang. The conference exerts significant influence in promoting the high-quality development of the biopharmaceutical industry and ensuring the quality and safety of biological products.

　　Wang Tao, Deputy Director General of the CDE of NMPA, Shi Yigong, academician of the Chinese Academy of Science and president of Westlake University, Jin Qinxian, deputy director general of Changping Laboratory, Cheng Tao, director of the Institute of Hematology, and other well-known experts at home and abroad made keynote reports. Officials and experts from the CDE, Center for Food and Drug Inspection and National Institute for Food and Drug Control give speeches and join discussions on cutting-edge primary research, biotechnology transformation and innovation, as well as the review, registration, inspection, and post-marketing regulation of biological products. More than 700 people from biological product regulatory authorities, academic groups, industry experts and scholars, and biological product enterprises from various countries and regions attend the conference.